Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-73P is a pseudogene related to U4 small nuclear RNAs, which are important components of the spliceosome complex and essential for pre-mRNA splicing in the cell nucleus[4]. Unlike functional copies such as RNU4-2, the '73' variant designated as a pseudogene lacks protein-coding or active RNA functions. Pseudogenes are DNA sequences similar to known genes but typically lack the ability to produce functional products due to mutations or truncations acquired during evolution. There are no reported molecular functions, disease associations, or evidence that RNU4-73P is a therapeutic target in current scientific literature. Most clinical and molecular disease associations, especially in neurodevelopmental disorders, are linked to functional genes such as RNU4-2 and not to pseudogene variants[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 73, pseudogene (RNU4-73P).